Morepen to launch new fatty lever drug ‘Resmetirom’

Thermo Fisher Scientific to invest $2 billion to expand US operation

Investment demonstrates confidence in America’s commitment to science and innovation

Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA

Pfizer Q1 2025 revenue drops 8% to $13.7 billion

Delivers robust earnings performance, successfully navigating a dynamic environment

Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr

The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide

Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe

The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited

Zydus Lifesciences to acquire 85.6 % stake in Amplitude Surgical

The closing of the Block Acquisition is now expected to be completed by Q3 2025

We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer

Bayer expects 2025 to be the most difficult year of its turnaround

Thyrocare Technologies Q4 FY25 consolidated PAT up at Rs. 21.70 Cr

For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores